Successful Therapy of Czech Patients with ROS1 Translocation by Crizotinib


Authors: M. Svaton;  M. Pešek
Authors‘ workplace: Klinika pneumologie a ftizeologie LF UK a FN Plzeň
Published in: Klin Onkol 2016; 29(1): 63-65
Category: Case Report
doi: 10.14735/amko201663

Overview

Targeted therapy of lung cancer has brought significant improvement in prognosis for a lot of patients with EGFR-sensitive mutations and ALK translocations. Other clinical studies have shown ROS1 translocation as another potential target. Our case report brings probably the first successful use of crizotininib in a patient with ROS1 translocation in the Czech Republic. Treatment was well-tolerated and persists continually. During the control PET/ CT scans, partial regression of the disease was observed. ROS1 translocation becomes another promising target for our patients. Therefore, in our opinion, serious discussion about its inclusion among the basic genetic testing in lung adenocarcinomas should occur.

Key words:
non-small cell lung cancer – ROS1 – crizotinib

The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manuscript met the ICMJE recommendation for biomedical papers.

Submitted:
3. 11. 2015

Accepted:
7. 12. 2015


Sources

1. Zhao C, Li X, Li J et al. Detect­ing ALK, ROS1 and RET fusion genes in cell block samples. Transl Oncol 2014; 7(3): 363– 367. doi: 10.1016/ j.tranon.2014.04.013.

2. Jakopovic M, Thomas A, Lopez-Chavez A. From platinum compounds to targeted therapies in advanced thoracic malignancies. Anticancer Res 2014; 34(1): 477– 482.

3. Roberts PJ, Stinchcombe TE, Der CJ et al. Personalized medicine in non-small cell lung cancer: is KRAS a useful marker in select­ing patients for epidermal growth factor receptor-targeted therapy? J Clin Oncol 2010; 28(31): 4769– 4777. doi: 10.1200/ JCO.2009.27.4365.

4. Rosell R, Carcereny E, Gervais R et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small cell lung cancer (EURTAC): a multicentre, open-label, randomized phase III trial. Lancet Oncol 2012; 13(3): 239– 246. doi: 10.1016/ S1470-2045(11)70393-X.

5. Bergethon K, Shaw AT, Ou SH et al. ROS1 rear­rangements define a unique molecular class of lung cancers. J Clin Oncol 2012; 30(8): 863– 870. doi: 10.1200/ JCO. 2011.35.6345.

6. Awad M­M, Shaw AT. ALK inhibitors in non-small cell lung cancer: crizotinib and beyond. Clin Adv Hematol Oncol 2014; 12(7): 429– 439.

7. Shaw AT, Ou SH, Bang YJ et al. Crizotinib in ROS1-rear­ranged non-smal­l-cell lung cancer. N Engl J Med 2014; 371(21): 1963– 1971. doi: 10.1056/ NEJMoa1406766.

8. Davies KD, Doebele RC. Molecular pathways: ROS1 fusion proteins in cancer. Clin Cancer Res 2013; 19(15): 4040– 4045. doi: 10.1158/ 1078-0432.CCR-12-2851.

9. El-Deeb IM, Yoo KH, Lee SH. ROS receptor tyrosine kinase: a new potential target for anticancer drugs. Med Res Rev 2011; 31(5): 794– 818. doi: 10.1002/ med.20206.

10. Acquaviva J, Wong R, Charest A. The multifaceted roles of the receptor tyrosine kinase ROS in development and cancer. Biochim Biophys Acta 2009; 1795(1): 37– 52. doi: 10.1016/ j.bbcan.2008.07.006.

11. Chin LP, Soo RA, Soong R et al. Target­ing ROS1 with anaplastic lymphoma kinase inhibitors: a promis­ing ther­apeutic strategy for a newly defined molecular subset of non-smal­l-cell lung cancer. J Thorac Oncol 2012; 7(11): 1625– 1630. doi: 10.1097/ JTO.0b013e31826baf83.

12. Mescam-Mancini L, Lantuéjoul S, Moro-Sibilot D et al. On the relevance of a test­ing algorithm for the detection of ROS1-rear­ranged lung adenocarcinomas. Lung Cancer 2014; 83(2): 168– 173. doi: 10.1016/ j.lungcan.2013.11.019.

13. Warth A, Muley T, Dienemann H et al. ROS1 expres­sion and translocations in non-smal­l-cell lung cancer: clinicopathological analysis of 1478 cases. Histopathology 2014; 65(2): 187– 194. doi: 10.1111/ his.12379.

14. Choi CM. Overview of ALK and ROS1 rear­ranged lung cancer. Tuberc Respir Dis (Seoul) 2013; 75(6): 236– 237. doi: 10.4046/ trd.2013.75.6.236.

15. Heigener DF, Reck M. Crizotinib. Recent Results Cancer Res 2014; 201: 197– 205. doi: 10.1007/ 978-3-642-54490-3_11.

16. Yasuda H, de Figueiredo-Pontes L­l, Kobayashi S et al. Preclinical rationale for use of the clinical­ly available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer. J Thorac Oncol 2012; 7(7): 1086– 1090. doi: 10.1097/ JTO.0b013e3182570919.

17. Rothschild SI, Gautschi O. Crizotinib in the treatment of non-smal­l-cell lung cancer. Clin Lung Cancer 2013; 14(5): 473– 480. doi: 10.1016/ j.cl­lc.2013.04.006.

18. Gridel­li C, Peters S, Sgambato A et al. ALK inhibitors in the treatment of advanced NSCLC. Cancer Treat Rev 2014; 40(2): 300– 306. doi: 10.1016/ j.ctrv.2013.07.002.

19. Cur­ran MP. Crizotinib: in local­ly advanced or metastatic non-small cell lung cancer. Drugs 2012; 72(1): 99– 107. doi: 10.2165/ 11207680-000000000-00000.

20. Esfahani K, Agulnik JS, Cohen V. A systemic review of resistance mechanisms and ongo­ing clinical trials in ALK--re­ar­ranged non-small cell lung cancer. Front Oncol 2014; 4: 174.

Labels
Paediatric clinical oncology Surgery Clinical oncology
Login
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account